Biophytis awarded €1.5m to combat sarcopenic obesity
26 September 2012
Biophytis, which is based in Biocitech technology park in
Paris, has been selected for a €1.5 million grant for its SARCOB project following the 12th
tender issued by France’s Single Interministerial Fund.
The purpose of the SARCOB project, sponsored by Medicen, one of
France’s competition clusters, is to develop products for
preventing and treating sarcopenic obesity.
This condition is
affecting growing numbers of elderly people and is characterized by
an accelerated loss of muscular mass and force, leading to a very
crippling decline in mobility. The prevalence of obesity among the
over-50s in Europe is around 16% for men and 18% for
women (according to the SHARE Wave Two Study, 2008). In the US, the
prevalence of obesity is estimated at 37% in people over 60
for 2010 (source: Journal of American Geriatrics Society, 2004).
The SARCOB project is led by Biophytis, a start-up specialized in
nutrition that has been located at Biocitech since 2009. Also
participating in the project is another start-up, Metabrain
Research, which provides preclinical research services, as well as
internationally renowned interdisciplinary university research teams
from the Université Pierre et Marie Curie in Paris (the Institute of
Myology, the Institute of Cardiometabolism and Nutrition, and the
Biosipe Laboratory), AgroParisTech and the National Agronomic
Research Institute (INRA) in Clermont-Ferrand.
These organizations are pooling their complementary expertise in
the areas of muscular ageing, obesity and nutrition to develop
innovative solutions based on natural substances of nutritional
interest for preventing and treating sarcopenic obesity.
“We are delighted to have obtained this funding for a project
that is aimed at both preventing and treating an old person’s
pathology, an area where there are many unmet needs,” said the
founder of Biophytis, Stanislas Veillet.
“With its focus on health and nutrition, Biophytis is emblematic
of the Biocitech technology park’s development towards new
approaches in human therapeutics,” said the president of Biocitech,
Jean-François Boussard. “Biocitech and its residents have created a
local network that encourages company development. We are pleased to
see that it facilitates the conclusion of agreements and funding
deals with top-drawer public and private institutions.”